 |
 |
 |
|||||||
|
|||||||
|
|
NEWS
25.10.2007 Ipsat Therapies Announces Positive Top-line Data from Phase IIb Study of Ipsat P1APress Release, Clinical Trials, 25th October 2007
17.9.2007 Ipsat is presenting "a Novel Strategy to Prevent Colonization by Clostridium difficile" at ICAAC 17-20th September 2007.
5.7.2007 Ipsat Therapies has completed patient recruiment in Phase IIb clinical trial.
31.3.2007 The effect of Ipsat P1A, a novel drug for prevention of antibiotic-induced intestinal pathogenic colonization, on the gut antibiotic levels after intravenous administration of beta lactam antibiotic/beta lactamase inhibitors in the dog.
23.3.2007 Ipsat Therapies is looking for a skilled professional CMC Drug Development Scientist
12.12.2006 Our Team of 30+ highly skilled researchers and scientist in Helsinki is looking for seasoned professionals to complement our expertise as R&D Director and Clinical Development Manager
3.12.2006 Ipsat Therapies commences patient recruitment in Phase IIb clinical trial using its lead product P1APress Release, Start of Phase IIB, 3rd December 2006
18.6.2006 Our Team of 30+ highly skilled researchers and scientist in Helsinki is looking for seasoned professionals to complement our expertise as Medical Director and Head Of Clinical Development
1.4.2006 Ampicillin treatment shifts bacterial communities in the fecesPoster, 16th European Congress of Clinical Microbiology and Infectious Diseases Nice, April 1– 4, 2006
24.1.2006 Nora Kaarela Appointed As The New Chief Executive Officer Of Ipsat Therapies Ltd.Press Release, CEO Appointed, 10th February 2006
24.1.2006 Ipsat Therapies Completes €3M Financing Round And Strenghtens Board Of DirectorsPress Release, Financing, 24th January 2006
16.12.2005 Oral Ipsat P1A is a novel product to prevent ampicillin-induced emergence of resistent klebsiella species in gut, results of phase II clinical trialPoster, 45th ICAAC Washington, DC. December 16 - 19, 2005 
December 2005 Orally Administered Recombinant Metallo-b-Lactamase Preserves Colonization Resistance of Piperacillin-Tazobactam-Treated MiceAAC p. 5190-5191, December 2005
5.4.2005 Ipsat Therapies Announces Positive Phase II Results For Lead Product Against Antibiotic Resistance And Hospital Acquired InfectionPress Release, Clinical Trials, 5th April 2005 Ipsat Therapies Oy Completes €7M Financing Round And Strenghtens Board Of Directors Press Release, Financing, 4th April 2005 Ipsat will present data at the 15th ECCMID in Copenhagen, April 2-5 2005; Ipsat will also attend the following conferences; - BioSquare 2005, Lyon, Apr 13 - 14, 2005. - 45th ICAAC Meeting, New Orleans, Louisiana, Sept 21 - 24, 2005.
13.10.2003 Ipsat Therapies Announces Positive Clinical Trial Results for the Prevention of Serious Infections Associated with Antibiotic Resistance.Ipsat Presents Data at Booth 19 from 10am to 12.30pm, 13th October, at the BioPartnering Europe Conference, Queen Elizabeth Centre, London. Click here for the press release
05.9.2003 Ipsat Therapies has been chosen to give Oral Presentations, Poster Presentations and/or Open House Presentations at the following Symposiums and Conferences: - BIO CEO & Investor Conference in New York, February 23-25.2004, Poster Presentation - BioSquare in Basel, March 10-12.2004, Oral Presentation
31.3.2003 Ipsat to hold on an integrated symposium entitled “The role of intestinal microflora in hospital infections and antibiotic resistance” at the 13th ECCMID in Glasgow in May.
10.9.2002 Marion Carson, MD, has started as Managing Director of Ipsat Therapies Oy/Ltd Marion Carson MD. Dr Carson joined Ipsat from FibroGen Europe where she was Vice President of Business Development. Prior to that she worked for Orion Pharma where her last position was assistant VP Business Development. She was also responsible for medical information in Corporate Communications and Investor Relations. After moving to Finland in 1990 Dr Carson held several Physician and Research positions in Helsinki University Central Hospital and Helsinki University from 1990-1997. Dr Carson holds a Medical degree and a Doctorate in Medicine from the National University of Ireland, Diploma in Internal Medicine from the Royal College of Physicians of Ireland and specialization in Clinical Chemistry from the University of Helsinki.
29.8.2002
31.5.2002
|
